UPDATE - ASLAN Pharmaceuticals Temporarily Pauses Recruitment of New Patients Into ASLAN004 Study Due to COVID-19
13 April 2020 - 11:17AM
ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage
immunology and oncology focused biopharmaceutical company
developing innovative treatments to transform the lives of
patients, today announced that recruitment of new patients into its
randomised, double-blind, placebo-controlled multiple ascending
dose (MAD) study of ASLAN004 in moderate to severe atopic
dermatitis has been paused in light of recently imposed government
restrictions in Singapore to contain the spread of the coronavirus
disease (COVID-19). ASLAN does not currently expect these measures
to materially affect the projected timelines for the readout of
interim, unblinded data later this year.
ASLAN was recruiting patients into the second of three dose
cohorts. Clinical studies in Singapore, other than those related to
COVID-19, have paused recruitment in line with the recent
restrictions on movement of the public to contain the spread of
COVID-19. ASLAN intends to resume screening of new patients as soon
as these restrictions are lifted, which is currently due to take
place on 4 May 2020.
In parallel, ASLAN has identified several clinical sites in
Australia, which could join the study mid-year to accelerate
recruitment.
Dr Carl Firth, Chief Executive Officer, ASLAN
Pharmaceuticals, said: “It is vital that hospitals and
other medical services focus their limited resources on helping the
millions affected by COVID-19. We are hopeful that by taking these
necessary measures, the outbreak will soon be brought under control
and we can resume our studies safely.”
Media and IR contacts
Emma
ThompsonSpurwing CommunicationsTel: +65 6751 2021Email:
ASLAN@spurwingcomms.com |
|
About ASLAN Pharmaceuticals ASLAN
Pharmaceuticals (Nasdaq:ASLN, TPEx:6497) is a clinical-stage
immunology and oncology focused biopharmaceutical company
developing innovative treatments to transform the lives of
patients. Led by a senior management team with extensive experience
in global development and commercialisation, ASLAN has a clinical
portfolio comprised of a first in class monoclonal therapy,
ASLAN004, that is being developed in atopic dermatitis and other
immunology indications, and a small molecule inhibitor targeting
oncology. ASLAN’s partners include Almirall, Array BioPharma,
Bristol-Myers Squibb, and CSL. For additional information please
visit www.aslanpharma.com.
Forward looking statements
This release and the accompanying financial information, if any,
contains forward-looking statements. These statements are based on
the current beliefs and expectations of the management of ASLAN
Pharmaceuticals Limited and/or its affiliates (the "Company").
These forward-looking statements may include, but are not limited
to, statements regarding the Company’s business strategy, the
Company’s plans to develop and commercialise its product
candidates, the safety and efficacy of the Company’s product
candidates, the Company’s plans and expected timing with respect to
regulatory filings and approvals, and the size and growth potential
of the markets for the Company’s product candidates. The Company’s
estimates, projections and other forward-looking statements are
based on management's current assumptions and expectations of
future events and trends, which affect or may affect the Company’s
business, strategy, operations or financial performance, and
inherently involve significant known and unknown risks and
uncertainties. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation the risk factors described in the
Company’s US Securities and Exchange Commission filings and reports
(Commission File No. 001-38475), including the Company’s prospectus
dated May 8, 2018 filed with the US Securities and Exchange
Commission on such date.
All statements other than statements of historical fact are
forward-looking statements. The words “believe,” “may,” “might,”
“could,” “will,” “aim,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “plan,” or the negative of those terms, and
similar expressions that convey uncertainty of future events or
outcomes are intended to identify estimates, projections and other
forward-looking statements. Estimates, projections and other
forward-looking statements speak only as of the date they were
made, and, except to the extent required by law, the Company
undertakes no obligation to update or review any estimate,
projection or forward-looking statement.
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024